HomeAI · summaries
Storia in 2 fonti
Candel reports prostate cancer drug's long-term data ahead of FDA filing
Candel Therapeutics' CEO says long-term data bode well for its prostate cancer drug aglatimagene ahead of an FDA submission.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
endpoints.news
Candel reports prostate cancer drug's long-term data ahead of FDA filing
Candel Therapeutics' CEO says long-term data bode well for its prostate cancer drug aglatimagene ahead of an FDA submission.
- ·
benzinga.com
Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data - Candel Therapeutics (NASDAQ:CAD
Candel Therapeutics presented positive phase 3 prostate cancer data showing improved disease-free survival, while analysts maintained bullish expectations on the stock.